Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 8 at 2:00 PM EDT

Register Free →
logo
Get CLEATUSFree Trial

Biological Technologies

Active
HR001126S0003Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is issuing a solicitation for proposals aimed at harnessing biological processes and properties to significantly enhance the protection and capabilities of the nation’s warfighters. This initiative seeks innovative approaches that go beyond incremental or evolutionary advancements to existing technologies, focusing instead on transformative breakthroughs that can revolutionize defense capabilities. The solicitation, titled "Biological Technologies," was posted on October 1, 2025, with a submission deadline of September 30, 2026. This opportunity is open under the Department of Defense’s DARPA BTO, without specific restrictions on organization types or set-asides, allowing broad participation from various sectors. While specific location requirements are not defined for the place of performance, interested parties can obtain further details or submit proposals by contacting the DARPA Biological Technologies Office via the provided email or phone number. The solicitation emphasizes creative and potentially disruptive biological research applications to fortify national defense and improve warfighter outcomes.

General Info

DARPA BTO seeks innovative biological technologies to transform and enhance warfighter protection capabilities.

Agency

Department Of Defense → Darpa - Biological Technologies OfficeView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(14)

HR001126S0003 Cooperative Agreement V2

DOCX•cooperative-agreement

HR001126S0003 DARPA Streamlined Cost Proposal Spreadsheet V3

XLSX•cost-proposal-spreadsheet

HR001126S0003 DARPA Model Other Transaction Agreement for Prototype

DOCX•contract-document

HR001126S0003 Baseline Model Contract Addendum

DOCX•contract-document

HR001126S0003 Model Other Transaction Agreement for Research

DOCX•contract-document

HR001126S0003 Abstract Submission Template for Biological Technologies BAA

DOCX•abstract-template

Contract HR00112CXXX Accelerated Baseline Model Small Business

PDF•contract-document

DARPA BTO Broad Agency Announcement HR001126S0003 Biological Technologies

PDF•baa

HR001126S0003 Controlled Unclassified Information Guide

PDF•other

HR001126S0003 Attachment C Volume II Cost Proposal Instructions and Template

DOCX•cost-proposal-template

HR001126S0003 Biological Technologies Proposal Instructions and Volume I Template

DOCX•proposal-instructions-template

HR001126S0003 Classified Submission Instructions

DOCX•submission-instructions

Contract HR00112CXXX Award Document

PDF•contract-document

HR001126S0003 Attachment G Accelerated Award Option Election and Attestation Form

DOCX•attachment

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Darpa - Biological Technologies Office
Contacts1 person available
OfficeUS
Organization / Agency
Department Of Defense → Darpa - Biological Technologies Office
View Agency Profile
Office AddressUS
Contacts
DARPA - Biological Technologies Office
contact@example.gov
+1 (555) 000-0000

Full Description

Show more
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is soliciting proposals that leverage biological properties and processes to revolutionize our ability to protect the nation’s warfighters. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.

Similar Contracts

NAICS: 541714
New
Federal
Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3The RAPIID program, specifically Task Area 3, aims to bridge the gap between lab-scale breakthroughs in shelf-stable blood analogs and real-world deployment by advancing the regulatory approval, manufacturing scalability, and field usability of components originally developed under the FSHARP program. These components, designed to replicate the critical functions of whole blood—oxygen delivery, hemostasis, and volume expansion—now require rigorous clinical validation to demonstrate safety and efficacy when used in combination, as well as scalable production processes to ensure consistent, high-volume output. Efforts under this solicitation will focus on pushing these technologies through the regulatory pathway to secure necessary approvals for military and civilian use in austere, pre-hospital environments. The initiative seeks to develop and scale enabling fielding technologies that support the deployment, storage, and administration of these blood analogs outside controlled laboratory settings. This includes not only the components themselves but also the logistical and operational frameworks needed to integrate them into frontline medical workflows. Proposals must address the full spectrum of challenges—from manufacturing robustness and regulatory compliance to usability in extreme conditions—while aligning with the program’s goal of delivering a complete, authorized system capable of saving lives where traditional blood supplies are unavailable. The solicitation, issued by DARPA’s Biological Technologies Office, has a response deadline of July 29, 2026, and is open to all qualified entities, targeting the NAICS code 541714 for research and development in physical, engineering, and life sciences.
Defense Advanced Research Projects Agcy

POSTED

3 days ago

DEADLINE

in 25 days
View Details
NAICS: 541714
New
Federal
Chromosome Conformation and Whole Genome Sequencing - KINGSTON RIThis contract solicitation seeks quotations for chromosome conformation and whole genome sequencing services under solicitation number 1232SA26Q0618, issued as a combined synopsis and request for quotation in accordance with FAR Part 12. The acquisition is exclusively reserved for small business concerns, with a total small business set-aside designation, and is restricted to entities that do not exceed 1,000 employees as defined by the North American Industry Classification System code 541714. All responsible small businesses are eligible to submit a quote, and no separate written solicitation will be issued—this announcement serves as the complete and only solicitation document. The work is to be performed in Kingston, Rhode Island, with the contracting office located in Beltsville, Maryland, under the auspices of the USDA Agricultural Research Service. The solicitation was posted on July 2, 2026, and responses are due by July 10, 2026, at 10:00 PM Eastern Time. All inquiries should be directed to Shane Pope, the primary point of contact, via email at shane.pope@usda.gov or by phone at 970-851-3735. The opportunity is accessible through the SAM.gov platform, and bidders must ensure full compliance with federal commercial item procurement guidelines.
USDA Ars Afm Apd

POSTED

3 days ago

DEADLINE

in 6 days
View Details
NAICS: 541714
New
Federal
RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)The Biomedical Advanced Research and Development Authority (BARDA), under the U.S. Department of Health and Human Services, is seeking proposals through Request for Proposal 75A50126R00002 to advance the late-stage clinical development and regulatory approval of 2-PAM autoinjectors as a drug/device combination product for the treatment of organophosphate poisoning, including nerve agents, in both adult and pediatric populations. The contract also encompasses the procurement of these autoinjectors for inclusion in the Strategic National Stockpile (SNS) and CHEMPACK programs. The solicitation requires offerors to demonstrate the capability to manufacture 600 mg 2-PAM autoinjectors at a Phase 3 clinical level or higher, with full FDA approval readiness. Proposals must include a comprehensive technical approach covering risk mitigation, project management, inventory control, and post-market surveillance, with mandatory compliance with current Good Manufacturing Practices and FDA guidance for emergency use or approved medical products. The contract features a base period of up to 36 months with up to three optional periods extending performance to a total of 10 years, involving a total potential procurement of 2 million adult-dose autoinjectors across four separate firm-fixed-price line items, each for 500,000 units, supported by cost-plus-fixed-fee line items for development and post-market activities. Deliveries are FOB destination to BARDA’s facility in Washington, D.C., with the contractor responsible for product integrity, temperature control (8–25°C), and security—including GPS tracking, tamper-resistant sealing, and TempTale documentation—until formal government acceptance. Evaluation is conducted on a best-value trade-off basis, with mandatory technical and infrastructure criteria serving as disqualifying thresholds, followed by technical approach, past performance, and cost. Offerors must be current in SAM with a valid UEI and CAGE code, and are subject to strict organizational conflict of interest disclosures, key personnel notification requirements, and prohibitions on the use of funds for abortions, needle distribution for illegal drug use, or human embryo research. Proposals must be submitted electronically via the BDR Portal by July 30, 2026, structured in three distinct volumes under strict page limits, with compliance to HHSAR and FAR clauses governing supply chain risk, anti-lobbying, and inspection standards.
Barda - Aspr / Daappo / Barda Dcma

POSTED

3 days ago

DEADLINE

in 26 days
View Details
NAICS: 541714
New
Grant
NIDDK Disease Research and Translational Core Centers (P30 Clinical Trial Optional)The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is inviting applications for Disease Research and Translational Core Centers under the P30 mechanism, which is clinical trial optional. These centers aim to strengthen existing research institutions with established programs in cystic fibrosis, diabetes, nutrition, obesity, liver, and digestive diseases by fostering multidisciplinary collaboration, improving research rigor and reproducibility, and enhancing cost efficiency. The centers are structured around shared core services that provide access to specialized equipment, technical resources, analytical support, and expert-led training, all tailored to the specific needs of the research community within the institution. They also include a Pilot and Feasibility Grant Program to support new projects and a Scientific Catalyst Program administered through the Administrative Core, which promotes team building, mentoring, workshops, seminars, and visits by expert scientists to stimulate innovation and attract new investigators to the field. The program places strong emphasis on creating a nurturing environment for trainees and early-stage investigators, ensuring that emerging researchers benefit from mentorship and integrated scientific networks. Core services must be operated or overseen by recognized experts and are designed to be shared across center members to maximize impact and efficiency. The Scientific Catalyst Program specifically supports activities that build research capacity, encourage cross-disciplinary partnerships, and align scientific efforts with the center’s focus on chronic diseases. Applications are expected to demonstrate how the proposed infrastructure will enhance existing strengths and expand the institute’s research trajectory. The funding opportunity was posted on July 2, 2026, and inquiries should be directed to the designated NIDDK contact for further details.
National Institutes Of Health

POSTED

3 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Bioinformatics and Genomics support services - Navy Medical Research CommandThe U.S. Navy, through the Naval Supply Systems Command Fleet Logistics Center Norfolk, is seeking information to support the future acquisition of high-quality bioinformatics and genomics services for the Naval Medical Research Command at Fort Detrick, Maryland. This request is issued as a Request for Information (RFI) under solicitation number 20260000382, with responses due by July 7, 2026, and is explicitly not a solicitation or request for quotation, meaning no contract will be awarded based solely on this effort, nor will respondents be reimbursed for preparation costs. The anticipated contract will be a Cost Plus Fixed Fee (CPFF) non-personal services task order with a total potential duration of up to 66 months, including a 12-month base period beginning September 30, 2026, four additional 12-month option periods, and one optional six-month extension. The contractor will provide subject matter expertise in molecular biology, virology, genomics, bioinformatics, software development, bacteriology, field collection, outbreak response, and assay development to support research and development efforts at the NMRC BDRD. Key deliverables include conducting high-throughput ‘omics’ analyses on pathogens and environmental samples, developing artificial intelligence models to predict phage-host interactions, supporting pandemic preparedness for threats like SARS-CoV-2 and filoviruses, deploying Next Generation Sequencing and bioinformatics capabilities in resource-limited global settings, and delivering 24/7/365 reach-back support to field operators with user guides and fieldable software. The contractor must provide 20.5 full-time equivalent personnel, with annual travel estimated at $75,000 and other direct costs at $750,000 per 12-month period. All personnel must be U.S. citizens, eligible for Secret clearance, and pass required background investigations, with certain positions requiring NACLC, T3, or T3R equivalency. The contractor is required to maintain a DCAA-approved accounting system and will be subject to a Quality Assurance Surveillance Plan using 100% inspection of monthly status reports and random sampling to evaluate performance. Monthly status reports must include travel pre-approvals, cost vouchers, task progress, and cost control efforts and are due no later than 30 days after each month-end. No reimbursement will be provided for start-up costs, and invoicing will commence only upon performance start
Navsup Flt Logistics Ctr Norfolk

POSTED

4 days ago

DEADLINE

in 3 days
View Details